BRENUS-PHARMA
9.4.2024 14:30:33 CEST | Business Wire | Press release
Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).
“Efficacy of the STC-10101 a new allogeneic cancer vaccine in different colorectal cancer models” | Abstract 5003 https://doi.org/10.1158/1538-7445.AM2024-5003
This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with in-ovo model.
Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.
- George ALZEEB2, galzeeb@brenus-pharma.com, Innovation Manager Manager (Ph.D)
- Céline GONGORA3, celine.gongora@inserm.fr, Research Director, Head of Team Inserm U1194 “Drug resistances and new cancer treatment” (Ph.D)
- Corentin RICHARD4, CRichard@cgfl.fr, Postdoctoral Bioiformatician (Ph.D)
- Romain BOIDOT3, rboidot@cgfl.fr, Molecular Biologist (Ph.D)
- Tanguy FORTIN5, tanguy.fortin@anaquant.com, Chief Executive Officer (Ph.D)
- Yan WANG6, yan.wang@inovotion.com, Scientist/R&D Project Manager (Ph.D)
- Alban BESSEDE7, a.bessede@explicyte.com, Chief Executive Officer (Ph.D)
- Benoit PINTEUR1, bpinteur@brenus-pharma.com, Chief Scientific Officer (Pharm D)
- Lionel CHALUS1, lchalus@brenus-pharma.com, Head of Technical Operation
- Corinne TORTORELLI1, ctortorelli@brenus-pharma.com, Senior Medical Lead (Pharm.D., Ph.D)
- Paul BRAVETTI1, pbravetti@brenus-pharma.com, Chief Executive Officer (Pharm D, MSc)
- François GHIRINGHELLI8, FGhiringhelli@cgfl.fr, Head of Team Inserm 1231 TIRECs «Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology (M.D, PhD)
https://www.brenus-pharma.com/ | Follow us on LinkedIn
1 STC-1010 is a next-generation cancer immunotherapy produced by Allogeneic STC's proprietary Brenus platform. It’s specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication. STC Platform mimics relapse conditions and allows eduction of patient’s immune system against resistant tumor.
2 Brenus Pharma, Lyon, France,
3 INSERM U1194 IRCM, Montpellier, France,
4 CNRS 6302, Dijon, France,
5 Anaquant, Lyon, France
6 Inovotion, La Tronche, France,
7 Explicyte, Bordeaux, France
8 Inserm 1231 CGFL, Dijon, France
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409632375/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom